Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.
|Study Design:||Primary Purpose: Treatment|
|Study Start Date:||October 2000|
|Estimated Study Completion Date:||September 2002|
Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity.
Completion date provided represents the completion date of the grant per OOPD records
Please refer to this study by its ClinicalTrials.gov identifier: NCT00014729
|Study Chair:||Jo-David Fine||University of North Carolina|